Ejner Bech Jensen
Adenium Biotech, Novozymes
Mr Jensen is head of Novozymes research organization on a global scale. Novozymes A/S develops biological solutions that enable the transformation from a petrochemical to a bio based society. Novozymes works with all aspects of modern biotechnology and are embracing the most advanced technologies that supports enzyme discovery, metabolic engineering and recombinant production of proteins. The organization has 5 different sites and approximately 450 employees worldwide. Mr Jensen is responsible for technology development and research strategies covering many biotechnology disciplins mainly focusing on industrial biotech, but a part of the organization works in the biopharmaceutical field. This includes anti infectives, human defensins and technologies for improved functionalities such as albumin fusion. Currently we only focus on these enabling technologies that can be used to improve existing biopharmaceuticals and not new drug discovery. Mr Jensen has worked more than 25 years in the Novo family of companies. Prior to Novozymes Mr Jensen worked in Nordisk Gentofte (hGH, Insulin, different growth factors), and later in Novo Nordisk. Mr Jensen became Director of Molecular Biotechnology in 1995 but returned to California as the President of the R&D group in 2006. Main focus here is molecular biology, metabolic engineering to produce chemicals and cellulosic biofuel.
Designed by Prestigia OnlineCreated by the EFB TeamCopyright © 2017 European Federation of Biotechnology
20 September, 2017